Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLaëtitia LargeaudLDLucie DonatyVMVéronique Mansat‐De Mas

Discussion

Loading...

Member takes

Overview

Analysis reveals minimal residual disease affects survival outcomes in patients with NPM1-mutated AML, suggesting enhanced monitoring methods are needed.

Key Points

  • NPM1-mutated AML patients with positive minimal residual disease had significantly worse survival outcomes, highlighting the importance of monitoring.
  • Patients in complete remission with chemotherapy showed divergent outcomes based on minimal residual disease positivity, influencing prognosis.
  • Flow cytometry and molecular biology techniques for minimal residual disease assessment were utilized in a large registry of NPM1-mutated AML patients.
  • Combining these methods can better stratify risk and guide clinical decisions for patients post-induction treatment.

Cite This Study

Largeaud et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0bdhttps://doi.org/10.1182/blood-2025-1744
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation2025 · 1 citations
  2. 2Early flow cytometry-based MRD predicts relapse in intermediate-risk AML from low- and middle-income countries2025
  3. 3Outcomes following MRD relapse in AML patients monitored by droplet digital PCR2025
  4. 4A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia2025 · 2 citations
  5. 5A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study2025 · 1 citations